The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
BCE Inc.
![USA/Canada U.S.A., Canada flags](https://www.greenhill.com/sites/default/files/usa_canada.gif)
Advised the Board of BCE on a review of a range of strategic alternatives that culminated in an agreement to sell to a consortium consisting of Teacher's Private Capital, Providence Equity Partners and Madison Dearborn Partners for $52.0 billion that was ultimately terminated
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Brookfield Canada Office Properties
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Pure Industrial Real Estate Trust
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
EPCOR Power L.P.
Advised the Independent Committee of the Board of Directors of EPCOR Power L.P., an Alberta-based power trust, on approval of the transfer of its GP interest and 30.6% LP interest from EPCOR Utilities to a newly formed company, Capital Power Corporation
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Whistler Blackcomb Holdings Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Niska Gas Storage Partners
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield
![](https://www.greenhill.com/sites/default/files/lang-ca-us.png)
Brookfield Property Partners L.P.
![](https://www.greenhill.com/sites/default/files/lang-ca-us.png)
Advised the Special Committee of Brookfield Property Partners L.P., one of the world’s premier commercial real estate companies, on its repurchase of up to $890 million of publicly held units, funded with an equity investment from Brookfield Asset Management and its affiliates
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Camelot Group plc
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Aritzia Inc.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised the Special Committee of Aritzia, an innovative designer and retailer of fashion brands, on the secondary offering and concurrent repurchase of shares held by Berkshire Partners
![USA/Canada U.S.A., Canada flags](https://www.greenhill.com/sites/default/files/usa_canada.gif)
Concordia International Corp
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process